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Abstract
We performed integrative network analyses to identify targets
that can be used for effectively treating liver diseases with mini-
mal side effects. We first generated co-expression networks (CNs)
for 46 human tissues and liver cancer to explore the functional
relationships between genes and examined the overlap between
functional and physical interactions. Since increased de novo lipo-
genesis is a characteristic of nonalcoholic fatty liver disease
(NAFLD) and hepatocellular carcinoma (HCC), we investigated the
liver-specific genes co-expressed with fatty acid synthase (FASN).
CN analyses predicted that inhibition of these liver-specific genes
decreases FASN expression. Experiments in human cancer cell
lines, mouse liver samples, and primary human hepatocytes vali-
dated our predictions by demonstrating functional relationships
between these liver genes, and showing that their inhibition
decreases cell growth and liver fat content. In conclusion, we
identified liver-specific genes linked to NAFLD pathogenesis, such
as pyruvate kinase liver and red blood cell (PKLR), or to HCC
pathogenesis, such as PKLR, patatin-like phospholipase domain
containing 3 (PNPLA3), and proprotein convertase subtilisin/kexin
type 9 (PCSK9), all of which are potential targets for drug
development.
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Introduction
Nonalcoholic fatty liver disease (NAFLD) is characterized by the
accumulation of excess fat in the liver and is associated with
obesity, insulin resistance (IR), and type 2 diabetes (T2D). NAFLD
includes a spectrum of diseases ranging from simple steatosis to
nonalcoholic steatohepatitis (NASH) and plays a major role in the
progression of cirrhosis and hepatocellular carcinoma (HCC), a
cancer with one of the highest mortality rates worldwide (Kew,
2010). Although NAFLD is the most common cause of chronic liver
disease in developed countries, and its worldwide prevalence
continues to increase along with the growing obesity epidemic,
there is no approved pharmacological treatment for NAFLD. NAFLD
is projected to become the most common indication leading to liver
transplantation in the United States by 2030 (Shaker et al, 2014).
The incidence of HCC has also increased significantly in the United
States over the past few decades, in parallel with the epidemic of
NAFLD (Petrick et al, 2016). Hence, there is an urgent need to
develop new strategies for preventing and treating such chronic
hepatic diseases.
Biological networks can be used to uncover complex systems-
level properties. Systems biology combining experimental and
computational biology to decipher the complexity of biological
systems can be used for the development of effective treatment
strategies for NAFLD, HCC, and other complex diseases (Mardinoglu
& Nielsen, 2015; Yizhak et al, 2015; Mardinoglu et al, 2017b;
Nielsen, 2017). To date, several metabolic processes that are altered
in NAFLD (Mardinoglu et al, 2014a, 2017a; Hyo¨tyla¨inen et al, 2016)
and HCC (Agren et al, 2012, 2014; Bjo¨rnson et al, 2015; Elsemman
et al, 2016) have been revealed through the use of genome-scale
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metabolic models (GEMs), a popular tool in systems biology. GEMs
are reconstructed on the basis of detailed biochemical information
and have been widely used to determine the underlying molecular
mechanisms of metabolism-related disorders (Mardinoglu &
Nielsen, 2012, 2015, 2016; Mardinoglu et al, 2013b, 2015; Yizhak
et al, 2013, 2014a,b; Bordbar et al, 2014; Bjo¨rnson et al, 2015;
O’Brien et al, 2015; Shoaie et al, 2015; Zhang et al, 2015; Uhlen
et al, 2016).
Recently, we have integrated GEMs for hepatocytes (iHepato-
cytes2322; Mardinoglu et al, 2014a), myocytes (iMyocytes2419;
Varemo et al, 2015), and adipocytes (iAdipocytes1850; Mardinoglu
et al, 2013a, 2014b) with transcriptional regulatory networks
(TRNs) and protein–protein interaction networks (PPINs) to gener-
ate tissue-specific integrated networks (INs) for liver, muscle, and
adipose tissues (Lee et al, 2016). The INs allowed us to comprehen-
sively explore the tissue biological processes altered in the liver and
adipose tissues of obese subjects, thus accounting for the effects of
transcriptional regulators and their interacting proteins and
enzymes. Although INs provide physical interactions between pairs
or groups of enzymes, transcription factors (TFs), and other
proteins, these physical interactions may not necessarily have close
functional connections.
Co-expression connections are enriched for functionally related
genes, and co-expression networks (CNs) allow the simultaneous
investigation of multiple gene co-expression patterns across a wide
range of clinical and environmental conditions. In this study, we
constructed CNs for major human tissues including liver, muscle, and
adipose tissues and studied the overlap between functional connec-
tions and physical interactions defined by CNs and INs, respectively.
We also constructed CNs for HCC to investigate the functional rela-
tionship between genes. Finally, we used these comprehensive biolog-
ical networks to explore the altered biological processes in NAFLD
and HCC and identified liver-specific gene targets that may be used in
the development of effective treatment strategies for NAFLD and HCC
with likely minimal negative side effects.
Results
Generation of CNs for human tissues
A common observation in gene expression analysis performed for
different clinical conditions is that many genes known to be func-
tionally related often show similar expression patterns, thus poten-
tially indicating shared biological functions under common
regulatory control. Thus, identifying co-expression patterns instead
of only differential expression patterns may be informative for
understanding altered biological functions. To identify genes with
similar gene expression profiles, we retrieved RNA-seq data
comprising 51 tissues, including liver, muscle, and subcutaneous
and omental adipose, along with other major human tissue samples
(Dataset EV1), from the Genotype-Tissue Expression (GTEx) data-
base (GTEx, 2013). To measure the tendency of gene expression
correlation, we calculated the Pearson correlation coefficients (r)
between all gene pairs in 46 human tissues (Dataset EV1) with more
than 50 samples, and we ranked all genes according to the calcu-
lated r. We used the top 1% correlation value of each tissue as a
cutoff indicating that two genes were co-expressed (average
r = 0.576 for 46 tissues) and therefore had the same number of co-
expression links for all tissues, thus yielding 1,498,790 links, and
combined them to construct the tissue-specific CNs. The resulting
CNs were as follows: Liver tissue contained 11,580 co-expressed
genes, muscle tissue contained 10,728 co-expressed genes, and
subcutaneous and omental adipose tissue contained 12,120 and
11,117 co-expressed genes (Dataset EV1).
Given the connectivity of tissue-specific co-expression links, we
found groups of highly co-expressed genes, termed co-expression
clusters, by using the random walk community detection algorithm
(Pons & Latapy, 2005; Fig 1A). Among these clusters, we selected
the most highly co-expressed key clusters on the basis of their clus-
tering coefficients (average clustering coefficient = 0.522). We
found that genes associated with key co-expression clusters in
tissues significantly overlapped with tissue-specific genes presented
in the Human Protein Atlas (HPA; Uhlen et al, 2015), when global
proteomics and transcriptomics data were available for more than
30 human tissues. Our analysis indicated that 75.6% of 41 HPA-
matched tissues had key co-expression clusters significantly
enriched in tissue-specific genes (hypergeometric test P < 0.01),
thus suggesting the tissue-specific roles of the genes associated with
the key clusters (Dataset EV2).
To investigate tissue-specific functions of the genes associated
with the key co-expression clusters, we performed gene ontology
(GO) enrichment analysis by using the GO biological processes (BP)
terms in MSigDB (Subramanian et al, 2005; hypergeometric test
P < 1.0 × 104; Fig EV1). For example, in liver tissue, we found that
genes associated with key co-expression clusters were enriched in
terms comprising the immune response, hemopoiesis, and fatty acid
metabolic processes (Fig 1B), whereas in testis tissue, co-expression
clusters were enriched in cell cycle, metabolism, and reproduction
(Fig EV1C and Dataset EV3). Likewise, we investigated the enrich-
ment of the genes associated with key co-expression clusters in
other metabolically active tissues, including skeletal muscle and
subcutaneous and omental adipose tissues, compared with the
significantly enriched GO BP terms in liver tissue, and found that
the GO BP term “hemopoiesis” was enriched only in liver tissue,
whereas “muscle development” was enriched only in skeletal
muscle (Fig EV1A). In both subcutaneous adipose tissue and liver
tissue, genes associated with the key clusters were significantly
enriched in fatty acid metabolic processes (Fig EV1B). Hence, our
analysis indicated that genes involved in fatty acid metabolism are
significantly co-expressed in liver and adipose tissues.
Increased co-regulation results in increased co-expression
We have previously presented INs for metabolic tissues, including
liver, muscle, and adipose tissues, and have identified the physical
links between TFs and target proteins and enzymes (Lee et al,
2016). Here, we investigated the overlap between the INs and CNs
and analyzed the potential deregulation of metabolism in metaboli-
cally active human tissues by using the topology on the basis of the
regulatory interactions and protein–protein interactions of INs by
comparing the mean co-expression of actual networks with that of
networks randomly permutated by 1,000 repetitions (Fig 1C). We
found that most of the actual tissue regulatory networks (RNs;
Fig 1D) and PPINs (Fig 1E) showed higher co-expression than
randomly permutated networks in liver and other metabolic tissues
Molecular Systems Biology 13: 938 | 2017 ª 2017 The Authors
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(Figs EV2A and B, and EV3A and B). We also observed that regula-
tory interactions built from in vitro differentiated adipocytes (Lee
et al, 2016) had less specificity than co-expression calculated by
using subcutaneous adipose tissue RNA-seq data demonstrating
higher tissue specificity (Fig EV2B).
Target proteins regulated by the same TFs or interacting with the
same proteins may have similar gene expression patterns (Zhang
et al, 2016). Hence, we examined the co-expression of co-regulated
gene pairs in RNs and found that their mean co-expression was
higher in actual RNs than in randomly permutated RNs in the liver
(Fig 1F) and other metabolic tissues (Fig EV2C and D). Moreover,
we examined the co-expression of gene pairs that were not regulated
by the same TFs and found that their mean co-expression was lower
in actual liver RNs than in randomly permutated RNs in liver tissue
(Fig 1H) and other metabolic tissues (Fig EV2E and F). Similarly,
we examined the co-expression of co-interacting gene pairs for the
same proteins in PPINs and found relatively lower mean co-expres-
sion in actual liver PPINs than in randomly permutated PPINs in
liver tissue (Fig 1G) and other metabolic tissues (Fig EV3C and D),
as compared with the mean co-expression of the actual RNs. We
also found that mean co-expression in PPINs was lower in actual
PPINs than in randomly permutated PPINs in liver tissue (Fig 1I)
and other metabolic tissues (Fig EV3E and F) when we compared
proteins that did not interact with the same proteins. Our analysis
indicated that physical interactions defined by the RNs and PPINs
can be used to explain protein co-expression. Moreover, we
observed that the two target proteins regulated by the same TFs
may have similar expression patterns, whereas two target proteins
interacting with the same protein may have less similar expression
patterns.
Target proteins may be regulated by more than one TF in RNs,
thus potentially affecting their expression patterns. In this context,
we determined the co-expression of two target proteins regulated
by the same TFs and found that an increased number of co-bound
TFs were likely to be associated with increased mean
co-expression levels in liver (Fig 1J), skeletal muscle, and adipose
tissues (Fig EV2G and H). We also repeated a similar analysis in
PPINs on the basis of the two target proteins that co-interacted
with the same proteins and found that the increased number of
co-interacting proteins was not directly proportional to increased
mean co-expression although the mean co-expression levels were
high in the liver (Fig 1K) and other tissues analyzed (Fig EV3G
and H). Our analysis indicates that protein interactions provide
evidence for increased co-expression by RNs compared with PPINs
in metabolic tissues.
We also identified the TFs and proteins that were highly co-
expressed with their target genes or proteins in RNs and PPINs,
respectively (|r| > 0.1 and Kolmogorov–Smirnov (KS) two-sided
test, P < 0.05) (Fig 1L, Datasets EV4 and EV5). We investigated the
biological functions associated with these TFs and proteins using
DAVID (Huang et al, 2009) and found that the TFs in liver RN were
enriched in the regulation of transcription and cell differentiation
(false discovery rate [FDR] < 0.01) and that the proteins in liver
PPIN were enriched in RNA splicing (FDR < 0.01), which is
involved in post-transcriptional regulation. To identify the most
influential TFs in the co-expression of gene pairs, we used the most
highly co-expressed gene pairs (top 1%), established the co-binding
matrix of bound TFs on the basis of RNs, and calculated the variable
importance score by using the Random Forest model in the liver
(Fig 1M and Dataset EV6). Among the top 1% most influential TFs
(76 TFs), for example, YY1, CTCF, RAD21, SREBF1, and SREBF2,
we found TFs enriched in liver development, interphase of the
mitotic cell cycle, and response to lipids (FDR < 0.001), thus
suggesting that many influential TFs are involved in liver-specific
functions.
Highly co-expressed metabolic pathways in the liver
On the basis of physical and functional links provided by the
networks, we examined which metabolic pathways are regulated
Figure 1. Characteristics of tissue-specific co-expression networks (CNs).
A We generated co-expression networks for 46 tissues that had more than 50 samples from GTEx RNA-seq data. In each tissue, we found groups of highly co-
expressed genes, called co-expression clusters, by using a community detection algorithm. Among these groups, we selected key co-expression clusters on the basis
of their clustering coefficients.
B For example, in liver tissue, we found genes from key co-expression clusters significantly enriched in biological processes required for liver function, such as fatty
acid metabolism, hemopoiesis, and immune response. All nodes in the network stand for co-expression clusters, and edges are connected when genes belonging to
those clusters were highly connected more frequently than at random. Node sizes are proportional to the number of genes involved in the respective clusters.
C–K In liver tissue, we investigated co-expression of physical interactions from the liver regulatory network (RN) or liver protein–protein interaction network (PPIN) (red
lines). We also generated randomly permutated gene pairs from those physical interactions by 1,000× (blue dashed lines) and compared them with actual gene
pairs from RN or PPIN (D and E, respectively). We identified co-regulatory interactions from RN or PPIN (F and G, respectively), which indicate gene pairs co-bound
by the same TFs or co-interacting with the same proteins, and compared them with randomly permutated gene pairs; here, we examined only the co-regulated
gene pairs with the highest numbers of co-bound TFs or co-interacting proteins (top 0.1%). In addition, we identified gene pairs that had no co-regulation by TF
binding or protein interactions (H and I, respectively) and compared them with randomly permutated gene pairs. We found that gene pairs from actual physical
interactions (D and E) or co-regulatory interactions (F and G) had higher co-expression than at random; however, gene pairs with no co-regulations (H and I) had
lower co-expression than at random. We examined the co-expression profiles of co-regulated gene pairs according to their co-bound TFs (J) or co-interacting
proteins (K). Here, we found that only co-regulations from RN were associated with increased co-expression, whereas co-regulations from PPIN were not, thus
suggesting that RN has more specificity for increasing co-expression.
L We examined which TFs or proteins were highly co-expressed with their bound target genes or interacting proteins by comparing their gene pairs with the overall
expression by Kolmogorov–Smirnov two-sided test (P < 0.05) and the absolute value of mean co-expression (|r| > 0.1).
M To find the most influential TFs in co-expression, we established a feature matrix between highly co-expressed gene pairs (top 1%) and their co-bound TFs and
fitted it to a Random Forest model; we considered co-bound TFs as predictor variables and co-expression values as response variables. From this model, we
calculated variable importance scores of TFs, and on the basis of these scores, we identified the most influential TFs in co-expression in liver tissue. The top 1%
most influential TFs included YY1, CTCF, RAD21, SREBF1, and SREBF2 and were enriched in liver development, interphase of the mitotic cell cycle, and response to
lipids.
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specifically in the liver. We first identified the group of metabolic
reactions catalyzed by highly co-expressed enzymes in liver tissue
by using the Human Metabolic Reaction database (HMR2;
Mardinoglu et al, 2014a). Taking the maximal co-expression of
enzymes between two metabolic reactions, we established a reac-
tion co-expression matrix among all reactions (Fig 2A). From this
matrix, we identified hundreds of clusters of reactions with highly
co-expressed enzymes by using hierarchical clustering (Dataset
EV7). By comparing their co-expression in liver tissue with the
co-expression in adipose subcutaneous and skeletal muscle
tissues, we identified metabolic reaction clusters that were co-
expressed only in liver tissue (Fig 2B). On the basis of Fisher
Z-transformed differences in tissue co-expression, we identified
ten reaction clusters of the most differential co-expression levels
between liver and muscle tissue (left, Fig 2B) or between liver
and adipose tissue (right, Fig 2B); four reaction clusters over-
lapped in both cases.
Among those clusters, we determined the TFs that were highly
co-bound with enzymes of those reaction clusters by using the
hypergeometric test (P < 0.05) and found that each reaction cluster
was governed by different sets of TFs (Fig 2C and Dataset EV8). For
example, metabolic nuclear receptors, such as the farnesoid X recep-
tor (FXR or NR1H4), pregnane X receptor (PXR or NR1I2), and
RXRB, were highly co-bound with enzymes catalyzing the reaction
in cluster 14, whereas SREBF2, a regulator of lipid homeostasis, was
highly co-bound with enzymes catalyzing reactions in cluster 9.
These findings indicated that enzymes catalyzing reactions in clus-
ters 14 and 9 would share regulatory controls in response to meta-
bolic alterations. Next, we determined which reaction clusters were
enriched in influential TFs that we had identified. Using variable
importance scores of TFs (Dataset EV6), we determined whether
highly co-bound TFs of reaction clusters (Dataset EV8) had variable
importance scores higher than the overall scores (KS one-sided test,
P < 0.25; Fig 2D). We found that reaction clusters including 9, 14,
40, and 58 had significantly enriched TFs with highly variable
importance scores, thus providing strong evidence of liver-specific
regulation from physical and co-expression links. Through meta-
bolic subsystem annotation from HMR2, we observed that reaction
cluster 9 was enriched in mitochondrial transport, pyruvate metabo-
lism, and lipid metabolism, cluster 14 was enriched in fatty acid
synthesis, cluster 40 was enriched in cholesterol metabolism, and
cluster 58 was enriched in amino acid metabolism (hypergeometric
test P < 0.01; Dataset EV9); these results indicated reactions
involved in pathways that are regulated in only the liver and are
primarily associated with lipid metabolism.
Next, we determined which liver reaction clusters were dereg-
ulated in HCC (Dataset EV7), on the basis of co-expression of
those clusters in HCC tumor tissue from The Cancer Genome
Atlas (TCGA; Fig 2E). We first retrieved RNA-seq data for 371
HCC tumors from TCGA and calculated Pearson’s correlation
coefficients between the gene pairs. As we identified liver-specific
co-expression clusters (Fig 2B), we identified 10 reaction clusters
that were deregulated in HCC tumors on the basis of Fisher
Z-transformed differences in co-expression between GTEx liver
data and TCGA HCC data (yellow and purple points in Fig 2E).
Among those deregulated clusters, five reaction clusters were
identified as liver-specific clusters as opposed to adipose and/or
muscle tissue clusters (purple points in Fig 2E): reaction clusters
9, 14, 56, 62, and 65. Of note, reaction clusters 9 and 14 were
identified on the basis of their regulation with strong evidence
regarding co-expression (Fig 2B) and physical (Fig 2D) clues. In
HCC, deregulation of these liver-specific reaction clusters primar-
ily associated with fatty acid synthesis may be linked to HCC
pathogenesis (Fig 2F).
Identification of liver-specific FASN inhibitors for the treatment
of NAFLD and HCC
The expression of fatty acid synthase (FASN), which catalyzes the
last step in de novo lipogenesis (DNL), is significantly upregulated
in NAFLD (Dorn et al, 2010) and HCC (Bjo¨rnson et al, 2015). We
have recently shown that short-term intervention with an isocal-
oric carbohydrate-restricted diet causes a large decrease in liver
fat accompanied by striking rapid metabolic improvements
(Mardinoglu et al, in preparation). We measured clinical character-
istics, body composition, liver fat, hepatic DNL, and hepatic
▸Figure 2. Highly co-expressed metabolic pathways in liver tissue with their co-regulating TFs.A Among human metabolic reactions with known enzymes (HMR2), we calculated the co-expression of respective enzymes in liver tissue and established a co-
expression matrix of those metabolic reactions for liver tissue. Performing hierarchical clustering on the matrix, we found 100 reaction clusters of highly co-
expressed enzymes in liver tissue. We compared the mean co-expression profiles of given reaction clusters in liver tissue with the co-expression profiles of clusters
in other tissues, such as skeletal muscle and adipose subcutaneous tissues. On the basis of their differential co-expression levels, we identified liver-specific reaction
clusters (B) and their co-regulating TFs (C and D).
B Among the 100 reaction clusters for liver tissue, we selected ten reaction clusters with the most differential co-expression between liver tissue and skeletal muscle
tissue (left) or between liver tissue and adipose subcutaneous tissue (right), regarding them as liver-specific reaction clusters, colored red and blue, respectively
(purple for those in both cases).
C We examined co-regulating TFs of liver-specific reaction clusters found in (B). Using the hypergeometric test, we identified co-regulating TFs significantly enriched
in given reaction clusters (P < 0.05). Here, we found that reaction cluster 14 was enriched in binding of metabolic nuclear receptors, such as PXR, FXR, and RXR,
whereas reaction cluster 9 was enriched in binding of SREBF2, a regulator of lipid homeostasis.
D We found additional evidence of strong regulation in some liver-specific reaction clusters, on the basis of variable TF importance scores. We compared the variable
importance scores (Dataset EV6) of enriched TFs in given reaction clusters with the overall score by using Kolmogorov–Smirnov tests and selected significant
clusters (P < 0.25) as highly regulated reaction clusters, including reaction clusters 9, 14, 40, and 58.
E, F We identified HCC-deregulated reaction clusters by comparing co-expression levels between liver tissue and HCC tumor tissue similarly to (B). Yellow-colored are
HCC-deregulated liver reaction clusters; green-colored are liver-specific clusters found in (B); and purple-colored are reaction clusters shown in both cases. Here, we
found that reaction clusters 9 and 14 were regulated in a liver-specific manner at the levels of co-expression (B) and co-regulation (D) but were deregulated in HCC
tumor tissues (E). Reaction clusters 9 and 14 included reactions associated with fatty acid synthesis, including glucose uptake, pyruvate synthesis, and citrate
transport (F).
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b-oxidation and found that the diet caused rapid and significant
sustained decreases in liver fat, DNL, plasma triglycerides, and very
low-density lipoprotein triglycerides and a parallel increase in
b-hydroxybutyrate, an indicator of increased hepatic b-oxidation.
Hence, DNL may be targeted for the development of effective treat-
ment strategies for NAFLD and other chronic liver diseases, for
example, HCC.
However, small-molecule FASN inhibitors (e.g., C75, cerulenin)
suffer from pharmacological limitations that prevent their
development as systemic drugs (Pandey et al, 2012). These side
effects can also be explained by the high expression of FASN in
almost all major human tissues (Uhlen et al, 2015, 2016). Thus, we
hypothesized that the identification of liver-specific FASN inhibitors
might allow for the development of effective treatment strategies for
NAFLD and HCC. We identified highly co-expressed genes with
FASN on the basis of CNs generated using GTEx and TCGA data,
which have been used as representative datasets for NAFLD
(Dataset EV10) and HCC (Dataset EV11), respectively. Our CN
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analysis allowed the identification of genes functionally related to
FASN in liver and other major human tissues.
Using DAVID, we found that the top 100 genes co-expressed with
FASN in liver CN (Dataset EV10) were significantly enriched in GO
BP terms, including carboxylic acid, oxoacid, hexose, monosaccha-
ride, acyl-CoA and fatty acid metabolic processes, protein transport,
secretion, regulation of secretion, and negative regulation of cell
communication (Huang et al, 2009). We also compared the top 100
co-expressed genes with FASN in liver CN (Dataset EV10) with the
genes in 45 other tissue CNs (Dataset EV10) and identified pyruvate
kinase liver and red blood cell (PKLR), an enzyme phosphorylating
pyruvate from glycolysis to the TCA (citric acid) cycle and also in
fatty acid synthesis; PKLR is also shown in Fig 2F, as a liver-specific
gene co-expressed with FASN.
In HCC CN, we found that the top 100 genes co-expressed
with FASN (Dataset EV11) were significantly enriched in GO BP
terms, including animal organ development, carboxylic acid,
oxoacid, cholesterol, secondary alcohol, sterol and fatty acid
metabolic processes, along with steroid, sterol, and alcohol
biosynthetic processes. We also found ELOVL6, ACACA, and
SCD, involved in fatty acid biosynthesis, as the top genes co-
expressed with FASN in HCC CN (Dataset EV11). In addition, we
calculated Pearson’s correlations from log-transformed gene
expressions in HCC in order to check for robustly co-expressed
genes (Dataset EV12). We found that 40 of the genes in top-100
co-expressed genes were significantly co-expressed with FASN
before (Dataset EV11) and after log transformation (Dataset
EV12). We compared those robustly co-expressed genes with
FASN in HCC CN (Dataset EV12) with the top 100 co-expressed
genes in CNs of 46 human tissues (Dataset EV10) and found
PKLR, patatin-like phospholipase domain containing 3 (PNPLA3),
and proprotein convertase subtilisin/kexin type 9 (PCSK9),
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Figure 3. FASN CN in HCC tumor tissue.
A We present the 40 genes with the highest co-expression with FASN in HCC tumor tissue based on both log-transformed and raw expression values (Datasets EV11
and EV12). The lengths of edges were inversely proportional to the co-expression of corresponding gene pairs; thus, genes close to FASN were more co-expressed than
others. Node sizes were inversely proportional to adjusted p-values of differential expressions between patients between high (upper quartile) and low (lower
quartile) FASN expressions (Dataset EV13). We colored co-expressed genes on the basis of their liver specificity; red-colored genes were liver tissue-enriched (based on
HPA ver. 16 annotation) and co-expressed with FASN in fewer than three human tissues (Dataset EV10); FASN alone was colored blue.
B We show expressions of PKLR, PNPLA3, and PCSK9 in HCC patients with high and low FASN expressions. We found that liver-specific genes were significantly
(adjusted P < 1.0 × 1010) upregulated in patients high FASN expression compared to those with low FASN expression (Dataset EV13).
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referred to as liver-specific genes, as the only genes co-expressed
with FASN in less than three human tissues (Fig 3A).
Next, we compared the global gene expression profiling of the
HCC tumors in the upper quartile with highest expression of FASN
(n = 93) with the lower quartile with the lowest expression of FASN
(n = 93) using DESeq package (Anders & Huber, 2010) to analyze
the expression profile of liver-specific genes and their key role in
cancer progression. We found that the expression of PKLR, PNPLA3,
and PCSK9 was significantly increased in patients with high FASN
expression compared to those with low FASN expression (Fig 3B
and Dataset EV13).
We also determined the expression patterns of PKLR, PCSK9 and
PNPLA3 in the Human Protein Atlas, in which the expression of all
human protein coding genes have been measured in 32 major human
tissues, and these genes were identified as liver-specific genes based
on protein and mRNA expression (Kampf et al, 2014; Uhlen et al,
2015). Hence, these liver-specific genes, including PKLR, PNPLA3,
and PCSK9, may potentially be targeted for the treatment of HCC, and
PKLR may potentially be targeted for the treatment of NAFLD. Due to
the direct involvement of PKLR, PNPLA3, and PCSK9 in lipid
metabolism, we focused on the relationship between FASN and these
three liver-specific genes in the rest of our studies.
Validation of physical interactions by using human cancer
cell lines
We hypothesized that inhibition of liver-specific targets that are co-
expressed with FASN would inhibit FASN expression and decrease
fat synthesis. This inhibition would also inhibit tumor growth in the
case of HCC, because fatty acids play key roles in HCC progression
and development. To validate our hypothesis and to demonstrate
the physical interactions between FASN and liver-specific genes, we
first screened the cell lines with the highest PKLR mRNA expression
levels by using the data generated in the Human Protein Atlas
(Uhlen et al, 2015). We identified the K562 leukemia cell line as
having the highest PKLR expression using our recently published
data in Cell Atlas (Thul et al, 2017) and treated the cell line with
C75, a FASN inhibitor, at different concentrations for 24 h. The
purpose of this experiment was to test whether FASN inhibition
may affect the co-expressed genes with FASN (i.e., PKLR).
We found that FASN and PKLR expression levels were signifi-
cantly decreased (Fig 4A). Moreover, we determined that decreased
FASN and PKLR expression resulted in a significant decrease in cell
growth (Fig 4B). Next, we treated the HepG2 human cancer cell line
with C75 and found that FASN expression and the expression levels
of liver-specific genes, including PKLR, PNPLA3, and PCSK9, were
significantly decreased after 24 h (Fig 4C). Similarly, we found that
the growth of HepG2 cells was significantly decreased after treat-
ment of the cells with different concentrations of C75 (Fig 4D).
However, during the treatment of the cells with C75, other meta-
bolic pathways may also have been regulated, and gene expression
may have been affected by nonspecific binding of C75. In this context,
we used siRNA to decrease PKLR expression in the K562 cell line and
observed that FASN expression (Fig 4E) and cell growth (Fig 4F)
were significantly decreased, similarly to our observations after treat-
ing the cells with C75. Moreover, we inhibited PKLR expression in the
HepG2 cell line and found that FASN expression (Fig 4G) and cell
growth (Fig 4H) were significantly decreased, as expected.
Validation of physical interactions in mice and human
To show the functional relationship between FASN and the liver-
specific targets identified here in vivo, we fed mice (C57Bl/6N) a
zero-fat high-sucrose diet (HSD) for 2 weeks that induced the devel-
opment of fatty livers in mice (Fig 5A). We collected liver tissue
samples from the mice fed a HSD and compared the expression pro-
files of the genes in the liver of these mice with those in the liver of
mice fed a chow diet (CD). We observed that liver TG content in the
mice was significantly increased in the HSD fed group compared
with the control (Fig 5A). Next, we determined the expression pro-
files of FASN and our liver-specific gene targets and found that their
expression levels were significantly increased in mice fed the HSD
compared with mice fed the CD in parallel with the increase in liver
fat (Fig 5B).
It has been reported that circulating PCSK9 levels increase with the
severity of hepatic fat accumulation in patients at risk of NASH and
PCSK9 mRNA levels in liver have been linked with steatosis severity
(Ruscica et al, 2016). In this context, we fed the wild-type (WT) and
PCSK9 knockout (KO) mice a CD for 10 weeks. We collected liver
tissue samples from the WT and PCSK9 KO mice and compared the
expression levels of FASN and the other identified gene targets. We
determined the expression levels of these genes in PCSK9 KO mice
and found that they were significantly downregulated (Fig 5C).
Hence, our analysis suggested to targeting of PCSK9 for the develop-
ment of efficient treatment strategies for HCC patients.
Endocannabinoids acting on the hepatic cannabinoid-1 receptor
(CB1R) promote DNL by increasing the expression of genes involved
in lipid metabolism including FASN, SREBF1, and acetyl-CoA
carboxylase-1 (ACACA) (Osei-Hyiaman et al, 2005). CB1R has been
implicated in the pathology of different liver diseases with various
etiologies including NAFLD (Osei-Hyiaman et al, 2008), AFLD
(Jeong et al, 2008), viral hepatitis (Hezode et al, 2005), liver fibrosis
(Teixeira-Clerc et al, 2006), cirrhosis (Giannone et al, 2012), and
liver cancer (Mukhopadhyay et al, 2015). Activation of the endo-
cannabinoid/CB1R system inhibits fatty acid b-oxidation in the liver
(Osei-Hyiaman et al, 2008), interrupts hepatic carbohydrate and
cholesterol metabolism (Jourdan et al, 2012), and contributes to
diet-induced obesity and NAFLD. It has been observed that activa-
tion of hepatic CB1R promoted the initiation and progression of
chemically induced HCC in mice (Mukhopadhyay et al, 2015).
Considering the associations between CB1R, liver fibrosis, and HCC
even in the absence of obesity, we analyzed the expression of Fasn
as well as liver-specific gene targets in animal models of liver
cancer. We measured the expression of the Fasn and the liver-
specific gene targets including Pklr, Pcsk9, and Pnpla3 and found
that their expression was significantly (P < 0.05) increased in HCC
tumor compared to adjacent noncancerous samples obtained from
CB1R
+/+ mice (Fig 5D), with much smaller increases noted in corre-
sponding samples CB1R
/ mice. When we measured the expression
of these genes in HCC tumor and noncancerous samples obtained
from CB1R
/ mice, we found that the increase in the expression of
Fasn as well as liver-specific gene targets is attenuated in conjunction
with the decrease in tumor growth CB1R
/ mice (Fig 5E).
We finally validated our predictions by treating primary human
hepatocytes with C75 and found that the expression levels of FASN
PKLR, PCSK9 and PNPLA3 were significantly decreased (Fig 5F).
Liver diseases connected to FASN can thus be treated (by silencing
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Figure 4. Gene expression and proliferation of K562 and HepG2 cells after interference by C75 and PKLR-specific siRNA.
A FASN and PKLR expression levels in K562 cells after interference by different doses (0, 40, and 60 lM) of C75.
B Cell growth in K562 cells after interference by different doses (0, 20, 40, 60, and 80 lM) of C75.
C FASN, PKLR, PNPLA3, and PCSK9 expression levels in HepG2 cells after interference by different doses (0, 40, and 60 lM) of C75.
D Cell growth in HepG2 cells after interference by different doses (0, 20, 40, 60, and 80 lM) of C75.
E FASN and PKLR expression levels in K562 cells after interference by PKLR-specific siRNA (siRNA 53, siRNA 54).
F Cell growth in K562 cells after interference by PKLR-specific siRNA (siRNA 53, siRNA 54).
G FASN, PKLR, PNPLA3, and PCSK9 expression levels in HepG2 cells after interference by PKLR-specific siRNA (siRNA 53, siRNA 54).
H Cell growth in HepG2 cells after interference by PKLR-specific siRNA (siRNA 53, siRNA 54).
Data information: RNA was isolated for RT–PCR after interference for 24 h; GAPDH was set as the internal reference. Cell counting was performed after interference for
72 h. Data are presented as the means  standard errors of five independent experiments. Comparisons were performed by one-way ANOVA. Samples without any
interference were assigned as controls. * represents a significant difference compared with the value in the control group (P < 0.05).
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PKLR, PCSK9 or PNPLA3) without experiencing the side effects
associated with direct FASN inhibition.
Discussion
Rapid advances in omics technologies along with the adoption of
large shared public databases have allowed for the generation and
aggregation of massive sample datasets that can be used to construct
comprehensive biological networks. These networks may provide a
scaffold for the integration of omics data, thereby revealing the
underlying molecular mechanisms involved in disease appearance
and providing a better understanding of the variations in healthy and
diseased tissue that may be used in the development of effective
treatment strategies. In this study, we generated tissue-specific CNs
for 46 major human tissues and human liver cancer and explored the
tissue-specific functions by using the topologies provided by these
networks. An important aspect of a gene CN is modularity: Genes
that are highly interconnected within the network are usually
involved in the same biological modules or pathways. We compared
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Figure 5. The relationship between the genes in mice and human samples.
A TG content in the liver tissue of mice fed a zero-fat high-sucrose diet (HSD) and chow diet (CD) for 2 weeks (n = 10).
B–F The hepatic mRNA expressions of the Fasn, Pklr, Pcsk9, Pnpla3, and Hmgcr is measured in (B) mice fed a HSD and CD for 2 weeks, (C) Pcsk9 knockout and its
littermates (WT) fed a CD for 10 weeks, (D) wild-type HCC tumor and noncancerous samples, (E) CB1R knockout HCC tumor and noncancerous samples, and (F)
primary human hepatocytes treated with C75 for 4, 6, 8, and 24 h.
Data information: Data are presented as the means  standard errors of independent experiments. Student’s t-test; *P < 0.05, **P <0.01, ***P < 0.001 represents a
significant difference compared with the value in the control group.
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the tissue-specific CNs with the recently generated INs and found
that physical interactions revealed meaningful functional relation-
ships between genes. Next, using CNs, we investigated the emergent
properties and behaviors of the affected genes in response to NAFLD
and HCC at the system level rather than focusing on their individual
functions and clinical utilities. The use of CNs also allowed us to
obtain detailed information about the systems-level properties of
such complex liver diseases.
Correlation analysis is used to identify co-expressions between
different genes based on mRNA expression data. Although
co-expression does not necessarily indicate a relationship among
transcript levels, functional relationships between encoded protein-
coding genes have been shown in our study. Co-expression analysis
is applied to identify important alterations related to lipid metabo-
lism, and promotion of cell survival and cell growth. In order to
avoid possible false positives from co-expressed genes, we applied
strict cutoff of Pearson’s correlation coefficients, but it would be
necessary to develop advanced method to identify co-expressed
genes for smaller number of false positives. Here, we calculated
correlations of gene expressions using normal tissue samples
obtained from general population (i.e., GTEx) without selection
bias, thus expected to identify general functional relationships, not
only associated with a specific clinical indication. However, it is
noteworthy that RNA-seq data generated for large and extensively
phenotyped cohorts would improve our understanding of functional
relationships between genes in a specific clinical indication.
Considering the increased prevalence of NAFLD in the worldwide
as a hidden epidemic (Younossi et al, 2016), it is not implausible to
predict that NAFLD may become responsible for the future clinical
and economical burden of HCC (Younossi et al, 2015). It is also
reported that HCC patients with NAFLD have poor outcome for
disease progression (Younossi et al, 2015). Therefore, it is important
to identify common biological pathways and gene targets as driving
forces in the pathologies for developing effective therapeutic modali-
ties. In this context, system biology may contribute to identification
of novel targets that can be used in the development of efficient
treatment strategies. Our recent analysis described in Mardinoglu
et al (in preparation) and previous analysis (Mardinoglu et al,
2014a) indicated that DNL is a key pathway involved in the progres-
sion of the NAFLD. Previous analysis has also revealed DNL as one
of the most tightly regulated pathways in HCC compared with
noncancerous liver tissue (Bjo¨rnson et al, 2015). FASN (rate-
limiting enzyme in DNL) is believed to play key roles in NAFLD
progression and development and HCC; therefore, inhibiting FASN
may downregulate the DNL, decrease the accumulated fat within
the cells, and decrease tumor growth. To improve the success rate
of NAFLD and HCC treatment and to improve the survival prognosis
of HCC patients, identification of nontoxic FASN inhibitors is
required. To identify possible inhibitors, correlation analysis was
applied to mRNA expression data derived from liver tissue with
varying degree of fat and tumor samples. Co-expression analysis in
these samples revealed that FASN is co-expressed with a number of
genes that play roles in crucial biological processes involved in fat
accumulation and cancer cell metabolism.
We analyzed the majority of publicly available liver tissue gene
expression data, performed correlation analysis, and ultimately
generated co-expression networks for FASN. We identified a number
of liver-specific gene targets that can be inhibited with chemical
compounds or monoclonal antibodies including PKLR, PCSK9, and
PNPLA3, for effective treatment of chronic liver diseases. We finally
validated our predictions by demonstrating the functional relation-
ships among the expression of these genes and FASN, liver fat, and
cell growth, by using human cancer cell lines, mouse liver samples
(four different mouse studies), and human hepatocytes.
Wang et al (2002) have provided evidence that variants in the
PKLR gene are associated with an increased risk of T2D, which has
a pathogenesis similar to that of NAFLD. Ruscica et al (2016) have
associated circulating PCSK9 levels with accumulated liver fat. In
201 consecutive patients biopsied for suspected NASH, liver damage
has been quantified by NAFLD activity score, circulating PCSK9 by
ELISA, and hepatic mRNA by qRT–PCR in 76 of the patients. Circu-
lating PCSK9 has been found to be significantly associated with
hepatic steatosis grade, necroinflammation, ballooning, and fibrosis
stage (Ruscica et al, 2016). Circulating PCSK9 has also been found
to be significantly associated with hepatic expression of SREBP-1c
and FASN, whereas PCSK9 mRNA levels have been found to be
significantly correlated with steatosis severity and hepatic APOB,
SREBP-1c, and FASN expression (Ruscica et al, 2016). Aragones
et al (2016) have evaluated the association between liver PNPLA3
expression, key genes in lipid metabolism, and the presence of
NAFLD in morbidly obese women and have reported that PNPLA3
expression was related to HS in these subjects. Their analysis indi-
cates that PNPLA3 may be related to lipid accumulation in the liver,
mainly in the development and progression of simple steatosis.
PNPLA3 was also emphasized as a genetic determinant of risk factor
for the severity of NAFLD (Salameh et al, 2016). Furthermore,
higher prevalence for HCC development and poorer prognosis was
reported to be associated with PNPLA3 polymorphism in viral and
nonviral chronic liver diseases (Khlaiphuengsin et al, 2015). A
potential unifying factor upstream of these genes is the cannabi-
noid-1 receptor, stimulation of which was found to upregulate
several of the above-listed target proteins, including Fasn, Pklr,
Pnpla3, and Pcsk9 in mouse models of obesity/metabolic syndrome
and HCC, as documented and detailed.
Moreover, we found a number of genes, for example, ACACA,
were significantly co-expressed with FASN. It has been suggested
that inhibition of ACACA may be useful in treating a variety of
metabolic disorders, including metabolic syndrome, type 2 diabetes
mellitus, and fatty liver disease (Harriman et al, 2016). However,
our analysis indicated that potential inhibition of ACACA may have
severe side effects in other human tissues as the inhibitors of FASN.
In conclusion, we demonstrated a strategy whereby tissue-
specific CNs can be used to identify deregulations of biological func-
tions in response to disease and reveal the effects on relevant
expression of genes in liver. Eventually, we identified liver-specific
drug targets that can be used in effective treatment of liver diseases
including NAFLD and HCC.
Materials and Methods
Tissue-specific CNs
RNA-seq data from human tissues were downloaded from the GTEx
database, and their reads per kilobase per million (RPKM) values
were transformed into transcripts per kilobase per million (TPM)
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values. From each RNA-seq dataset, we excluded one-third of the
genes with the lowest expression levels from calculating Pearson’s
correlation coefficients of gene expression and combined the highest
correlated gene pairs into a respective tissue CN.
On the basis of the network connectivity of each tissue CN, we
clustered co-expressed genes by using the modularity-based random
walk method from the cluster walktrap function of the igraph pack-
age in R (Pons & Latapy, 2005). Among those gene groups, we
selected the half of the highest connected groups as key co-expres-
sion clusters, on the basis of their clustering coefficients. We
produced a liver CN with those co-expression clusters as nodes and
their significant connections by edges (Fig 1B). For example, the
edges of two co-expression clusters, A and B, were identified if their
observed connections (OAB) were twice as high as the expected
connections (EAB). Expected connections were defined by the
normalized sum of multiplications of the degree of connectivity of
genes in two clusters (i.e., EAB = Σ ka × kb/2N; a 2 A, b 2, N = all
edges in the network). Next, we collected genes belonging to key
co-expression clusters in each tissue and tested whether they were
enriched in biological process GO terms in MSigDB (Subramanian
et al, 2005) by using hypergeometric tests.
Comparing physical networks with CNs
We used RNs and PPINs of liver, skeletal muscle, and adipose tissues
from our prior published data (Lee et al, 2016) as sources of physical
interaction network data. We identified co-regulated gene pairs from
the physical interactions by selecting genes sharing TF binding (from
RNs) or genes sharing protein interactions (from PPINs); on the basis
of the number of co-bound TFs or co-interacting proteins, called co-
regulators, we selected the highest co-regulated gene pairs (i.e., gene
pairs with the highest numbers of co-bound TFs or co-interacting
proteins; top 0.1%) and gene pairs with no co-regulation. Using
Pearson’s correlation coefficients of the gene expression level of each
tissue from GTEx, we calculated the mean Pearson’s correlation coef-
ficients of gene pairs of interest, such as physically linked gene pairs
or co-regulated gene pairs. The edges of physical networks or their
co-regulatory networks were randomly permutated among genes in
respective actual networks by 1,000×, and their mean correlation
coefficients were compared with those from original networks. We
also identified TFs or proteins highly co-expressed with respective
bound genes by comparing the co-expression levels of given gene
pairs to overall levels (Datasets EV4 and EV5). We selected TFs or
proteins if co-expression levels of given linked gene pairs were
higher than the overall levels by using Kolmogorov–Smirnov (KS)
tests (P < 0.05) and absolute values of mean Pearson’s correlation
coefficients (> 0.1). Finally, we examined mean co-expression levels
of co-regulated gene pairs according to their number of co-regulators.
Increasing the cutoff number of co-regulators, we selected co-regu-
lated gene pairs exceeding the cutoff and calculated mean Pearson’s
correlation coefficients of the corresponding gene pairs.
Finding the most influential TFs for co-expression on the basis of
variable importance score
For liver tissue, we constructed a feature matrix between the most
highly co-expressed gene pairs (top 1%) and their co-bound TFs. In
this matrix, we assigned a value of 1 for given co-expressed gene
pairs that were co-bound by TFs and zero otherwise. For each co-
expressed gene pair, we considered co-bound TFs as predictor vari-
ables and the co-expression value as the response variable and fitted
them to the Random Forest model. From the model, we calculated
variable importance scores of all TFs and used them as a metric to
show the most influential TFs for co-expression.
Identifying liver-specific reaction clusters on the basis of tissue
co-expression of enzymes
From the HMR2 database, we collected human metabolic reactions
with known enzymes. Between the two reactions, we calculated
Pearson’s correlation coefficients of enzyme gene expression in liver
tissue, and if there were multiple enzymes for a single reaction, we
took the maximum value among possible co-expressions. On the
basis of co-expression values among metabolic reactions, we
performed hierarchical clustering and classified reactions into 100
clusters for liver tissue. To compare the co-expression values of
metabolic reactions in different tissues and tumor tissue, we calcu-
lated the co-expression values in not only liver tissue but also
adipose subcutaneous, skeletal muscle, and HCC tumor tissues.
Subsequently, we identified the differences in mean co-expression
values of given reaction clusters between liver tissue and other
tissues after transforming co-expression values into Fisher Z-values.
On the basis of differential Fisher Z-values, we took the top 1% of
reaction clusters of the highest in each comparison (adipose or
muscle tissues) and identified them as liver-specific reaction clus-
ters. Likewise, we identified an HCC-deregulated reaction cluster on
the basis of differential Fisher Z-values (top 1%).
Finally, using liver RN, we examined TFs highly bound at genes
encoding enzymes in given liver reaction clusters and identified TFs
whose binding was significantly enriched in given clusters by hyper-
geometric tests. From those enriched TFs, we selected reaction clus-
ters in which the enriched TFs had higher variable importance
scores than overall scores according to KS tests (P < 0.25) and
denoted them as highly regulated reaction clusters in liver tissue.
FASN co-expressed genes in human tissues and HCC tumors
In each normal tissue (GTEx) or HCC tumor tissue (TCGA), we
calculated Pearson’s correlation coefficients of gene expression
between FASN and other protein-coding genes expressing more than
1 TPM and selected the top 100 most correlated genes (Datasets
EV10 and EV11). In addition, we calculated correlations of log-trans-
formed expression values in HCC tumors (Dataset EV12). To select
tissue-specific genes, we examined the top 100 most correlated
genes to FASN in HCC tumor tissue by the RNA tissue category in
the Human Protein Atlas (ver. 16); in particular, genes “tissue-
enhanced” or “tissue-enriched” in liver tissue were selected (Fig 3).
We also examined those genes with tissues that were most corre-
lated (Dataset EV10) and selected genes that were present in fewer
than three human tissues.
Differential expression analysis of HCC patients stratified based
on FASN expressions
Using raw count data from HCC patients, we stratified patients into
two groups: patients having FASN expression above the upper
Molecular Systems Biology 13: 938 | 2017 ª 2017 The Authors
Molecular Systems Biology Identification of liver-specific drug targets Sunjae Lee et al
12
Published online: August 21, 2017 
quartile and patients having FASN expression under the lower quar-
tile. Between the two groups, we examined differentially expressed
genes by negative binomial test using DESeq (Anders & Huber,
2010; Dataset EV13).
Cell line experiments
For subsequent experiments, we selected K562 and HepG2, human
immortalized myelogenous leukemia and hepatic cell lines, res-
pectively. Both cell lines were cultured in RPMI-1640 medium
(R2405; Sigma-Aldrich) supplemented with 10% fetal bovine serum
(FBS, F2442; Sigma-Aldrich) and incubated in 5% CO2 humidity at
37°C.
To confirm the speculated CN, we chose chemical inhibitors and
RNA interference (RNAi) assays to interfere with the immortalized
cell lines (including K562 and HepG2) and observed the subsequent
candidate gene expression and cell growth patterns. More specifi-
cally, the experimental protocol was as follows: (i) C75 (C5490;
Sigma-Aldrich), as a well-known fatty acid synthase [FAS] inhibitor,
was added to cells at 80% confluence with a final concentration of
20, 40, 60, or 80 lM (taking cells without C75 interference as the
control); and (ii) cells at 80% confluence were separately trans-
fected with three pairs of Silencer pre-designed PKLR-targeted
siRNAs (clone ID: 53, 54; Life Technologies; Dataset EV14) at
15 nM by using Lipofectamine RNAiMAX (13778075; Life Tech-
nologies). Cells incubated in medium with nontarget negative
control siRNA at 15 nM (4390843; Life Technologies) were assigned
as the control.
Total RNA was isolated with TRIzol reagent (15596026, Thermo
Fisher Scientific) after treatment with C75 or siRNA for 24 h. The
expression profiles of key genes (FASN, PKLR in K562/HepG2, and
PNPLA3, PCSK9 only in HepG2 cells) in the co-expression network
were measured and analyzed via quantitative real-time PCR with
iTaq Universal SYBR Green One-Step Kit (1725151; Bio-Rad), using
anchored oligo (dT) primer based on CFX96TM detection system
(Bio-Rad). GAPDH was set as the internal control for normalization,
and the primer sequences are listed in Dataset EV15. Variation in
cell proliferation was detected with a Cell Counting Kit-8 (CCK-8,
CK04; Dojindo) after interference by C75/siRNA for 72 h. All experi-
ments were performed strictly according to the manufacturer’s
instructions and were repeated at least in triplicate for three samples
and yielded similar results.
Mouse experiments
Twenty male C57BL/6N mice were fed a standard mouse chow diet
(Purina 7012; Harlan Teklad) and housed under a 12-h light–dark
cycle. From 8 weeks of age, the mice were fed either a HSD diet
(TD.88137; Harlan Laboratories, WI, USA) or CD for 2 weeks. The
mice were housed at the University of Gothenburg animal facility
(Lab of Exp Biomed) and supervised by university veterinarians and
professional staff. The health status of our mice is constantly moni-
tored according to the rules established by the Federation of Euro-
pean Laboratory Animal Science Associations. The experiments
were approved by the Gothenburg Ethical Committee on Animal
Experiments.
In liver cancer mouse model, we injected 25 mg/kg of DEN
(Sigma) to CB1R
+/+ and CB1R
/ littermates in C57BL/6J
background after 2 weeks of birth, verified the presence of the HCC
tumor, and measured its size with magnetic resonance imaging
(MRI) 8 months after the DEN administration (Mukhopadhyay et al,
2015). It has been observed that activation of hepatic CB1R promoted
the initiation and progression of chemically induced HCC in mice
(Mukhopadhyay et al, 2015). Total RNA was isolated from tumor
area and noncancerous area of liver tissue samples obtained from six
DEN-treated (HCC) CB1R
+/+ and six CB1R
/ mice (Mukhopadhyay
et al, 2015). rRNA-depleted RNA, 100 ng for each sample, was
treated with RNase III to generate 100- to 200-nt fragments, which
were pooled and processed for RNA sequencing. All data were
normalized based on housekeeping genes used by CLC Genomics
Workbench program (version 5.1; CLC Bio, Boston, USA). These
absolute numbers were extracted from the reads, and the data were
adjusted to non-HCC biopsies for each gene.
Human hepatocytes
Human primary hepatocytes were purchased from Biopredic Inter-
national. Twenty-four hours after arrival (48 h after isolation),
human hepatocytes were treated with 40 lg/ml of C75 or dimethyl
sulfoxide (DMSO) for 4, 6, 8, or 24 h.
mRNA expression in mouse liver and human primary hepatocytes
Total RNA was isolated from human hepatocytes and snap-frozen
mouse liver with an RNeasy Mini Kit (Qiagen). cDNA was synthe-
sized with a high-capacity cDNA Reverse Transcription Kit (Applied
Biosystems) and random primers. The mRNA expression levels of
genes of interest were analyzed via TaqMan real-time PCR in a
ViiATM7 System (Applied Biosystems). The TaqMan Gene Expression
assays used were Mm01263610_m1 (for mouse Pcsk9),
Mm00662319_m1 (mouse Fasn), Mm00443090_m1 (mouse Pklr),
Mm00504420_m1 (mouse Pnpla3), Mm01282499_m1 (mouse
Hmgcr), Hs00545399_m1 (human PCSK9), Hs01005622_m1 (human
FASN), Hs00176075_m1 (human PKLR), Hs00228747_m1 (human
PNPLA3), and Hs00168352_m1 (human HMGCR) (all from
Applied Biosystems). Hprt (mouse Mm03024075_m1) and GADPH
(human Hs02758991_g1) (Applied Biosystems) were used as internal
controls.
Data availability
The networks used in this study are provided on an interactive web
page at: http://inetmodels.com. Co-expression networks have also
been uploaded to the NDEx (ndexbio.org), and network IDs are
provided in Dataset EV1.
Expanded View for this article is available online.
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